Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 1576 • ACR Convergence 2023
Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria
Jang Woo Ha¹, Sung Soo Ahn², Jason Jungsik Song², Yong-Beom Park² and Sang-Won Lee³, ¹Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Recently, a joint group of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) proposed new criteria for…
Abstract Number: 0697 • ACR Convergence 2023
Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Adam Mayer¹, Weiming Hu², Kyle Bittinger², Rui Liang³, Naomi Amudala³, Shubhasree Banerjee³, Peter Merkel³ and Rennie Rhee³, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…
Abstract Number: 1577 • ACR Convergence 2023
Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome
Maria Romero Noboa¹, Shilpa Arora¹ and Augustine Manadan², ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Takayasu's arteritis (TAK) is an autoimmune disease that primarily affects the aorta and its major branches. It has an incidence of 1-3 per million…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 1578 • ACR Convergence 2023
Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis
Alejandra Espinosa-Orantes¹, David Vera-Bustamante², Jessica Roldan Ortega³, Maria Mejia-Avila⁴, Jose Raul Molina⁵, Evelyn Aranda Cano⁵, Adriana Miguel-Alvarez⁵, Ismael Valenzuela⁵, Viridiana Del Río-Guerrero⁶, Paloma Rodriguez⁵, Mauricio Mora-Ramirez⁵, Nilda Espinola-Zavaleta⁴, Luis H Silveira-torre⁶, Angélica Vargas Guerrero⁷ and Laura A Martínez-Martínez⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, ⁴Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁶Instituto Nacional de Cardiología, Mexico City, Mexico, ⁷Instituto Nacional de Cardiología, Mexico City, Mexico, ⁸Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Yanint Raksadawan, Sabahat Usmani, Harigopal Sandhyavenu, Thatiana Schulze Goni, Jalpan Patel, Hafiz Muhammad Waqar Younas and Amro Taha, Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…
Abstract Number: 1648 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update
Christian Dejaco¹, Sofia Ramiro², Milena Bond³, Philipp Bosch⁴, Cristina Ponte⁵, Sarah Mackie⁶, Thorsten Bley⁷, Daniel Blockmans⁸, Sara Brolin⁹, Ertugrul Cagri Bolek¹⁰, Rebecca Cassie¹¹, Maria C Cid¹², Juan Molina-Collada¹³, Bhaskar Dasgupta¹⁴, Berit Dalsgaard Nielsen¹⁵, Eugenio De Miguel¹⁶, Haner Direskeneli¹⁷, Christina Duftner¹⁸, Alojzija Hocevar¹⁹, Anna Molto²⁰, Valentin Sebastian Schäfer²¹, Luca Seitz²², Riemer H.J.A. Slart²³ and Wolfgang Schmidt²⁴, ¹Azienda Sanitaria Alto Adige, Brunico, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁴Medical University of Graz, Graz, Austria, ⁵Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany, ⁸Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ⁹Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden, ¹⁰1-Hacettepe University Vasculitis Research Centre, Ankara, Turkey/ 2-Vasculitis Translational Research Program, NIAMS, NIH, US, Ankara, Turkey, ¹¹n/a, Leicester, United Kingdom, ¹²Hospital Clinic Barcelona, Barcelona, Spain, ¹³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Mid & South Essex University Hospitals NHS Foundation Trust; Southend University Hospital, Westcliff-on-sea, United Kingdom, ¹⁵Department of Internal Medicine, Horsens, Denmark, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Medical University Innsbruck, Innsbruck, Austria, ¹⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²⁰HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²²Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²³University of Twente, Enschede, Netherlands, ²⁴Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: Imaging recommendations for primary large vessel vasculitis (LVV) were developed in 2018. Several new studies have emerged since then, and an update of the…
Abstract Number: 0706 • ACR Convergence 2023
Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Fernando López¹, Javier Loricera², Carmen Secada³, Lucía García-Alcalde⁴, María Núñez-Savar⁴, Ander Ucelay-Aristi⁴ and Ricardo Blanco⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Department of Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortitis is the inflammation of the aortic wall, and can be idiopathic or associated with a cluster of infectious and non-infectious diseases (1-3). Periaortitis,…
Abstract Number: 1882 • ACR Convergence 2023
Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations
Philipp Bosch¹, Milena Bond², Christian Dejaco³, Cristina Ponte⁴, Sarah Mackie⁵, Louise Falzon⁶, Wolfgang Schmidt⁷ and Sofia Ramiro⁸, ¹Medical University of Graz, Graz, Austria, ²Azienda sanitaria dell'Alto Adige, Merano, Italy, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Sheffield, Sheffield, United Kingdom, ⁷Immanuel Krankenhaus Berlin, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…
Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Gleice Clemente¹, Maria Teresa Terreri², Bruno Gualano³, Clovis Silva⁴ and Alexandre Wagner De Souza¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de São Paulo, São Paulo, ⁴Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Ana Luiza Altaffer¹, Alvaro Orjuela² and Marietta De Guzman², ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Robert Maughan¹, Andrew Porter¹, Chanaka Dahanayake², Claudia Ianonne¹, Ritu Alapat¹, Charis Pericleous¹, Taryn Youngstein³ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Imperial NHS Trust, London, United Kingdom
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Cameron Rankin¹, Peter Grayson², Bates Gribbons³, Kaitlin Quinn⁴, Christopher Redmond⁵ and Wanxia Tsai¹, ¹NIAMS/NIH, Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³McGovern Medical School, Colleyville, TX, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁵National Institutes of Health, Rockville, MD
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].